News and Trends 28 Aug 2017 Samsung Bioepis Gets European Approval for Biosimilar of Best-Selling Antibody …anti-TNF-α antibody launched by Samsung Bioepis, making it the first company with biosimilars of all blockbusters that that target TNF-α. The other two are Benepali, a biosimilar of Amgen and… August 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 30 May 2024 Covalent biologics: a new class of drugs on the horizon …American company Enlaza Therapeutics’ undisclosed preclinical pipeline is mainly focused on antibody drug conjugates (ADCs). These drugs consist of an antibody that attaches to cancer cell targets, a chemotherapy drug… May 30, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2020 French Partnership Deploys AI for Antibody Drug Discovery …development — will help users identify a therapeutic target and select a candidate antibody that can enter production. OSE Immunotherapeutics hopes to deploy the partnership on fusion protein technology called… February 13, 2020 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 Clearance for anti-tumor bispecific antibody trial TG ImmunoPharma Co., Ltd. (TGI), which focuses on the development of novel immuno-oncology therapies, says the FDA has granted clearance for the clinical trial of TGI-6, its bispecific antibody. TGI-6… June 20, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Biotheus enters agreement with Hansoh Pharma for bispecific antibody …EGFR/MET bispecific antibody (also known as PM1080) in China, Hong Kong, Macao and Taiwan. Under the terms of the agreement, Hansoh will be granted by Biotheus the exclusive rights to… November 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2016 And the highest funding in Europe this year goes to… Antibody-Drug Conjugates! …(ADCT) is a Swiss Biotech that develops antibody-drug conjugates (ADCs) for oncology applications. Its founder Auven Therapeutics and its partner AstraZeneca have participated in the biggest funding round of the… October 19, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 5 Jun 2017 What Lies Ahead in Biotech for the UK’s Top Academic Entrepreneur? …company, Cambridge Antibody Technology (CAT), would go on to be the biggest success story in UK biotech after its team discovered the blockbuster therapeutic antibody, Humira, and became part of… June 5, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023 Ajinomoto and Exelixis to discover and develop novel ADCs to treat cancer …Ajinomoto Co.’s proprietary site-specific bioconjugation and stable linker technologies compatible with commonly used antibody isotypes. AJICAP technology includes its “off-the-shelf” feature, allowing any therapeutic antibody at any stage of development… January 12, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 29 May 2017 Meet the Founder of the UK’s Best Biotech that Discovered Humira …Antibody Technology (CAT), would go on to be the biggest success story in UK biotech after it discovered the blockbuster therapeutic antibody, Humira, and became part of AstraZeneca in 2006… May 29, 2017 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Sponsored by KBI Biopharma 17 Sep 2024 ADCs that deliver: The secret lies in rigorous characterization Antibody-drug conjugates (ADCs) represent an innovative class of potent anti-cancer agents. They combine the specificity of a monoclonal antibody with the potency of a cytotoxic drug, enabling targeted killing of… September 17, 2024 - 7 minutesmins - By Ute Boronowsky Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2016 Spain joins the Antibody-Drug Conjugate Bandwagon to fight Cancer …antibody-drug conjugate (ADC) candidate, MI130110, against fibrosarcoma and multiple myeloma. Which means the popular ADC field has managed to attract yet another company into what could be a major breakthrough… December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Sponsored by Lonza 26 Mar 2024 Large molecule manufacturing: addressing challenges with strategies for success …the characteristics of the molecule. This panel of offerings covers a broad range of protein modalities that include antibody-based products, such as bispecific antibodies, Fc-Fusion proteins, and antibody fragments, and… March 26, 2024 - 8 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email